Independent fund research. Built on SEC filings.

How we research funds

ETF · Small-Cap · BNY Mellon / Dreyfus

BNY Mellon US Small Cap Core Equity ETF (BKSE)

Ticker BKSE · Since 2020-04-07 · · Holdings as of Jul 31, 2026

Expense ratio
0.04%$4/yr per $10k
5-yr return
+7.5%annualized
1-yr return
+13.0%as of Dec 2025
Net assets
$87.3Mall share classes
Holdings
597

Bottom line

Is BKSE a good fund? The bottom line

BKSE is a managed small-cap ETF from BNY Mellon / Dreyfus.

Its expense ratio is 0.04% — about $4 a year on every $10,000 invested, cheaper than 98% of small-cap funds we track.

It returned +13.0% over one year, +7.5% a year over five years (as of Dec 31, 2025, per its prospectus).

With $87.3 million in net assets and 597 holdings, its largest position is Drey Inst Pref Gov Mm-m (1.1%) and the top 10 make up 4.7% of the portfolio.

What stands out

  • Low cost: cheaper than 98% of small-cap peers
  • Broadly diversified (597 holdings)

Updated Nov 19, 2026

What BKSE invests in

The fund seeks to track the performance of the Solactive GBS United States 600 Index TR.

To pursue its goal, the fund normally invests substantially all of its assets in equity securities comprising the Solactive GBS United States 600 Index TR (index). Under normal circumstances, the fund will invest at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of small-capitalization U.S. companies, ETFs providing exposure to such securities, and derivatives with economic characteristics similar to such securities. The fund considers small-capitalization companies to be companies with market capitalizations within the range of market capitalization of companies included in the index. As of December 31, 2025, the full market capitalization range of companies included in the index was $295 million to $8.77 billion. The fund considers a U.S. company to be a company whose securities are listed on a U.S. stock market. The Solactive GBS…

From the fund's prospectus (filed Feb 27, 2026).

BKSE performance

Fund calendar-year total returns, 2021–2025 2021: +16.3%; 2022: −18.4%; 2023: +22.4%; 2024: +9.6%; 2025: +13.0% +16.3% 2021 −18.4% 2022 +22.4% 2023 +9.6% 2024 +13.0% 2025
Fund gain (+) Fund loss (−)
Average annual total returns
1 yr5 yr10 yr
BKSE+13.0%+7.5%—
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full BKSE performance history →

What BKSE costs

On a $10,000 investment, BKSE's 0.04% expense ratio costs about $4 a year. The prospectus estimates $51 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full BKSE fee table →

BKSE top 10 holdings

#Holding% of fund
1Drey Inst Pref Gov Mm-m1.15%
2Hut 8 Corp HUT0.47%
3Corcept Therapeutics Inc CORT0.46%
4Glaukos Corp GKOS0.41%
5Avantor Inc AVTR0.40%
6Brinker International Inc EAT0.40%
7Timken Company (the) TKR0.38%
8Protagonist Therapeutics Inc PTGX0.36%
9Jfrog Ltd FROG0.35%
10Hanover Insurance Group Inc (the) THG0.35%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 4.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to BKSE

More funds like BKSE →

BKSE FAQ

What is the expense ratio of BKSE?
BKSE's expense ratio is 0.04%, which works out to about $4 a year for every $10,000 invested. The prospectus estimates total costs of $51 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is BKSE a good investment?
It depends on your goals, but the data points to: low cost: cheaper than 98% of small-cap peers; broadly diversified (597 holdings). This is general information, not personalized advice.
What does BKSE hold?
BKSE's largest holdings are Drey Inst Pref Gov Mm-m (1.1%), Hut 8 Corp (0.5%), Corcept Therapeutics Inc (0.5%), Glaukos Corp (0.4%), Avantor Inc (0.4%). It holds 597 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
What is BKSE's 5-year return?
BKSE returned +7.5% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Who manages BKSE?
BKSE is offered by BNY Mellon / Dreyfus through BNY Mellon ETF Trust.